Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors

Gastrointestinal stromal tumors represent the most common mesenchymal tumor of the digestive tract, driven by gain‐of‐function mutations in KIT. Despite its proven benefits, half of the patients treated with imatinib show disease progression within 2 years due to secondary resistance mutations in KI...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Tsuyoshi, Elzawahry, Asmaa, Mimaki, Sachiyo, Furukawa, Eisaku, Nakatsuka, Rie, Nakamura, Hiromi, Nishigaki, Takahiko, Serada, Satoshi, Naka, Tetsuji, Hirota, Seiichi, Shibata, Tatsuhiro, Tsuchihara, Katsuya, Nishida, Toshirou, Kato, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324566/
https://www.ncbi.nlm.nih.gov/pubmed/27997714
http://dx.doi.org/10.1002/gcc.22438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324566/
https://www.ncbi.nlm.nih.gov/pubmed/27997714
http://dx.doi.org/10.1002/gcc.22438

Ejemplares similares